Skip to main content

Corvus Pharmaceuticals, Inc.

corporate_fare Company Profile

Corvus Pharmaceuticals, Inc.

CRVS·NASDAQ·Life Sciences·CIK 0001626971

We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins critical to immune cell maturation and function. Our proprietary product candidates are designed to address immune mediated diseases, inflammatory diseases, and cancers. Our lead product candidate, soquelitinib (formerly CPI-818), specifically binds to interleukin 2 inducible T cell kinase (ITK), a protein involved in T cell activation, T cell receptor signaling, and T cell differentiation and function. We believe soquelitinib can inhibit the production of inflammatory cytokines involved in diseases such as atopic dermatitis, hidradenitis suppurativa, asthma, psoriasis, and fibrotic diseases. Preclinical studies showed soquelitinib affected T cell differentiation, enhancing the function of T cells involved in tumor cell eradication. Soquelitinib is in a registrational, Phase 3 clinical trial for relapsed T cell lymphomas and a recently initiated randomized, placebo-controlled Phase 2 trial in patients with atopic dermatitis. We have two additional product candidates in clinical development for various solid tumors, also based on modulating immune function. Soquelitinib (CPI-818) is an investigational selective, orally bioavailable, covalent inhibitor of ITK.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for CRVS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for CRVS spans 8-K, 10-Q, 424B5, 10-K.

Recent high-impact activity:

  • Corvus Q3 2026: $202.9M Cash Funds Operations Into Q2 2028 as Soquelitinib Trials Advance
  • Corvus Launches Phase 1B Trial of Soquelitinib in Hidradenitis Suppurativa
  • Corvus Invests $5M in Angel Pharma to Advance Soquelitinib Trials in China
  • Corvus Pharma's Soquelitinib Shows Durable Remissions, Favorable Safety in Phase 1 Trial
  • Corvus Pharma Reports Positive Phase 1 Data for Soquelitinib in Atopic Dermatitis, Highlighting Durable Remissions

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$15.28M
Diluted EPS
-$0.53
Op. Cash Flow
-$32.8M
Free Cash Flow
-$32.97M
Operating Income
-$42.97M
Cash & Equivalents
$4.58M
Debt / Equity
0.00×
Shares Outstanding
74.7M sh
Source: 10-K · filed 2026-03-12 · accession 0001104659-26-027047

Short Interest & Short Volume

18.85 days to cover

FINRA reported short interest of 17,759,451 shares in CRVS as of the October 30, 2026 settlement, a 1.2% decrease from the prior period — about 18.9 days to cover at its recent average daily volume. On November 20, 2026, 45.7% of CRVS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)17,759,451 shares as of October 30, 2026
Change vs prior period▼ 1.2%
Days to cover18.85 at avg daily volume of 942,325
Daily short volume (FINRA facilities)45.7% of 349,375 shares on November 20, 2026
5-day average short volume44.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$9.67
52-week range · as of 2026-11-05 $6.39 – $26.95
Market cap
$815.69M
Volume
927.5K (0.9× avg)
3-mo avg 988.6K
Live data · 2026-11-21 07:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRVS - Latest Insights

CRVS
Nov 05, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.80
Real-time Price: $9.67 info
Change: -$0.130 (-1%) info
Market Cap: $815.695M info
CRVS
Sep 30, 2026, 6:31 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $11.71
Real-time Price: $9.67 info
Change: -$2.04 (-17%) info
Market Cap: $815.695M info
CRVS
Jun 09, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.36
Real-time Price: $9.67 info
Change: -$1.69 (-15%) info
Market Cap: $815.695M info
CRVS
May 14, 2026, 7:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $16.25
Real-time Price: $9.67 info
Change: -$6.58 (-40%) info
Market Cap: $815.695M info
CRVS
May 14, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.12
Real-time Price: $9.67 info
Change: -$6.45 (-40%) info
Market Cap: $815.695M info
CRVS
May 07, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $15.02
Real-time Price: $9.67 info
Change: -$5.35 (-36%) info
Market Cap: $815.695M info
CRVS
May 07, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.59
Real-time Price: $9.67 info
Change: -$4.92 (-34%) info
Market Cap: $815.695M info
CRVS
Apr 23, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.07
Real-time Price: $9.67 info
Change: -$6.40 (-40%) info
Market Cap: $815.695M info
CRVS
Mar 13, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.66
Real-time Price: $9.67 info
Change: -$5.99 (-38%) info
Market Cap: $815.695M info
CRVS
Mar 13, 2026, 8:41 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $15.56
Real-time Price: $9.67 info
Change: -$5.89 (-38%) info
Market Cap: $815.695M info
CRVS
Mar 12, 2026, 4:48 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $15.80
Real-time Price: $9.67 info
Change: -$6.13 (-39%) info
Market Cap: $815.695M info
CRVS
Mar 12, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $15.80
Real-time Price: $9.67 info
Change: -$6.13 (-39%) info
Market Cap: $815.695M info
CRVS
Mar 12, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $16.80
Real-time Price: $9.67 info
Change: -$7.13 (-42%) info
Market Cap: $815.695M info
CRVS
Jan 27, 2026, 8:38 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $22.28
Real-time Price: $9.67 info
Change: -$12.61 (-57%) info
Market Cap: $815.695M info
CRVS
Jan 23, 2026, 6:03 AM EST
Filing Type: 424B5
Importance Score:
9
Price at Filing: $25.51
Real-time Price: $9.67 info
Change: -$15.84 (-62%) info
Market Cap: $815.695M info
CRVS
Jan 20, 2026, 4:55 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $19.69
Real-time Price: $9.67 info
Change: -$10.02 (-51%) info
Market Cap: $815.695M info
CRVS
Jan 20, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.31
Real-time Price: $9.67 info
Change: -$10.64 (-52%) info
Market Cap: $815.695M info
CRVS
Jan 20, 2026, 7:13 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.72
Real-time Price: $9.67 info
Change: -$1.05 (-10%) info
Market Cap: $815.695M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets